​

Marker Therapeutics (MRKR) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Marker Therapeutics Revenue Highlights

Latest Revenue (Y)

$3.55T

0

Main Segment (Y)

Grant

Marker Therapeutics Revenue by Period

Marker Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$3.55T53810034.30%
2024-12-31$6.59M99.06%
2023-12-31$3.31M-5.76%
2022-12-31$3.51M182.96%
2021-12-31$1.24M166.01%
2020-12-31$466.79K118.95%
2019-12-31$213.19K3.50%
2018-12-31$205.99K12.53%
2017-12-31$183.06K100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2010-12-31-100.00%
2009-12-31-100.00%
2008-12-31-100.00%
2007-12-31-100.00%
2006-12-31-100.00%
2005-12-31-100.00%
2004-12-31-100.00%
2003-12-31-100.00%
2002-12-31-100.00%
2001-12-31--100.00%
2000-12-31$31.81K-73.65%
1999-12-31$120.72K-

Marker Therapeutics generated $3.55T in revenue during NA 2025, up 53810034.30% compared to the previous quarter, and up 759807834.44% compared to the same period a year ago.

Marker Therapeutics Revenue by Quarter

DateRevenueChange
2026-03-31--100.00%
2025-12-31$1.10M-10.50%
2025-09-30$1.23M43.17%
2025-06-30$861.18K146.68%
2025-03-31$349.10K-84.50%
2024-12-31$2.25M16.91%
2024-09-30$1.93M64.72%
2024-06-30$1.17M-6.01%
2024-03-31$1.24M17.75%
2023-12-31$1.06M310.13%
2023-09-30$257.61K-66.22%
2023-06-30$762.66K-38.21%
2023-03-31$1.23M62.60%
2022-12-31$759.14K-24.05%
2022-09-30$999.57K26.45%
2022-06-30$790.51K-18.02%
2022-03-31$964.32K-22.34%
2021-12-31$1.24M100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30--100.00%
2020-06-30$466.79K100.00%
2020-03-31--100.00%
2019-12-31$213.19K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$6.00100.00%
2018-09-30--100.00%
2018-06-30$205.99K100.00%
2018-03-31-100.00%
2017-12-31--100.00%
2017-09-30$183.06K100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-10-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30-100.00%
2010-06-30-100.00%
2010-03-31-100.00%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31-100.00%
2007-12-31--

Marker Therapeutics generated - in revenue during Q1 2026, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Marker Therapeutics Revenue Breakdown

Marker Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Grant$3.55M$6.59M$3.51M--
Related Party Service--$3.50M--
Service--$816.64K$5.50M-
Grant income----$1.24M

Marker Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Grant (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$1.10M$1.23M$861.18K$349.10K$2.25M$1.93M$1.17M$1.24M$1.23M$759.14K$999.57K$213.19K---
Service---------$3.50M$2.55M----
Grant income------------$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Grant (100.00%).

Marker Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22Mar 22Dec 19
Grant$1.23M$759.14K$999.57K$213.19K--
Service$3.50M$2.55M----
Grant income---$790.51K$964.32K-

Marker Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Service (73.93%), and Grant (26.07%).

Marker Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRKRMarker Therapeutics$3.55T-
BOLTBolt Biotherapeutics$7.70M$26.00K
EVGNEvogene$5.64M$4.19M
IMNNImunon--
GLTOGalecto--
COCPCocrystal Pharma-$225.00K
PHIOPhio Pharmaceuticals--
CLRBCellectar Biosciences--
SNSESensei Biotherapeutics--
MBIOMustang Bio--

MRKR Revenue FAQ

What is Marker Therapeutics’s yearly revenue?

Marker Therapeutics's yearly revenue for 2025 was $3.55T, representing an increase of 53810034.30% compared to 2024. The company's yearly revenue for 2024 was $6.59M, representing an increase of 99.06% compared to 2023. MRKR's yearly revenue for 2023 was $3.31M, representing a decrease of -5.76% compared to 2022.

What is Marker Therapeutics’s quarterly revenue?

Marker Therapeutics's quarterly revenue for Q1 2026 was $0, a -100.00% decrease from the previous quarter (Q4 2025), and a -100.00% decrease year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $1.1M, a -10.50% decrease from the previous quarter (Q3 2025), and a -51.00% decrease year-over-year (Q4 2024). MRKR's quarterly revenue for Q3 2025 was $1.23M, a 43.17% increase from the previous quarter (Q2 2025), and a -35.98% decrease year-over-year (Q3 2024).

What is Marker Therapeutics’s revenue growth rate?

Marker Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 107113356.33%, and for the last 5 years (2021-2025) was 285627703.59%.

What are Marker Therapeutics’s revenue streams?

Marker Therapeutics's revenue streams in c 25 are Grant

What is Marker Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Marker Therapeutics was Grant. This segment made a revenue of $3.55M, representing 100.00% of the company's total revenue.